MARC record from Internet Archive

LEADER: 04535cam 2201009 a 4500
001 ocm32430019
003 OCoLC
005 20200520200143.0
008 950414s1995 nyua b 001 0 eng
010 $a 95016401
040 $aDLC$beng$cDLC$dCSZ$dAGL$dNLM$dUKM$dNLGGC$dBTCTA$dBAKER$dYDXCP$dUAB$dDEBBG$dZWZ$dOCLCQ$dBDX$dOCLCF$dOCLCQ$dOCLCO$dOCLCQ$dUKMGB$dTJC$dOCLCQ$dOCLCO$dBUF$dOCLCO$dWURST$dOCLCA$dL2U$dOCLCA
015 $aGB9567825$2bnb
016 7 $a9513086$2DNLM
016 7 $a006292492$2Uk
019 $a33162756$a1045216056
020 $a030644867X
020 $a9780306448676
035 $a(OCoLC)32430019$z(OCoLC)33162756$z(OCoLC)1045216056
050 00 $aQR189$b.V24 1995
060 00 $aW1$bPH151N v.6 1995
060 10 $aQW 805$bV1159 1995
070 0 $aRS380.P53$bv.6
072 0 $aX300
082 00 $a615/.372$220
084 $a44.42$2bcl
084 $aVS 9000$2rvk
245 00 $aVaccine design :$bthe subunit and adjuvant approach /$cedited by Michael F. Powell and Mark J. Newman ; assistant editor, Jessica R. Burdman ; with a foreword by Jonas Salk.
260 $aNew York :$bPlenum Press,$c©1995.
300 $axliv, 949 pages :$billustrations ;$c24 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
490 1 $aPharmaceutical biotechnology ;$vv. 6
490 1 $aThe language of science
504 $aIncludes bibliographical references and index.
505 0 $aCh. 1. Immunological and Formulation Design Considerations for Subunit Vaccines / Mark J. Newman and Michael F. Powell -- Ch. 2. Public Health Implications of Emerging Vaccine Technologies / Dale N. Lawrence, Karen L. Goldenthal, John W. Boslego, Donna K.F. Chandler and John R. La Montagne -- Ch. 3. Preclinical Safety Assessment Considerations in Vaccine Development / Jeanine L. Bussiere, George C. McCormick and James D. Green -- Ch. 4. Regulatory Considerations in Vaccine Design / Lawrence W. Davenport -- Ch. 5. Clinical Considerations in Vaccine Trials with Special Reference to Candidate HIV Vaccines / Patricia E. Fast, Leigh A. Sawyer and Susan L. Wescott -- Ch. 6. Laboratory Empiricism, Clinical Design, and Social Value: The Rough Road toward Vaccine Development / Donald P. Francis -- Ch. 7. A Compendium of Vaccine Adjuvants and Excipients / Frederick R. Vogel and Michael F. Powell.
650 0 $aVaccines.
650 0 $aImmunological adjuvants.
650 12 $aVaccines.
650 22 $aAdjuvants, Immunologic.
650 22 $aDrug Design.
650 7 $a44.42 pharmacy, pharmaceuticals.$0(NL-LeOCL)077596579$2bcl
650 7 $aImmunological adjuvants.$2fast$0(OCoLC)fst00967992
650 7 $aVaccines.$2fast$0(OCoLC)fst01163573
650 7 $aVaccins synthétiques.$2fmesh
650 7 $aAdjuvants immunologiques.$2fmesh
650 7 $aConception de médicament.$2fmesh
650 7 $aSystèmes de délivrance de médicaments.$2fmesh
650 7 $aArzneimitteldesign$2gnd
650 7 $aImpfstoff$2gnd
650 7 $aPharmazeutische Technologie$2gnd
650 17 $aVaccins.$2gtt
650 17 $aAdjuvantia.$2gtt
650 7 $aVaccins.$2ram
650 7 $aAdjuvants immunologiques.$2ram
653 0 $aVaccines
653 00 $avaccins
653 00 $avaccinontwikkeling
653 00 $avaccine development
653 00 $afarmacologie
653 00 $apharmacology
653 00 $abiotechnologie
653 00 $abiotechnology
653 10 $aPharmacology
653 20 $aVeterinary Pharmacology and Anaesthesiology
653 10 $aFarmacologie
653 20 $aVeterinaire farmacologie en anesthesiologie
700 1 $aPowell, Michael F.
700 1 $aNewman, Mark J.
700 1 $aBurdman, Jessica R.
776 08 $iOnline version:$tVaccine design.$dNew York : Plenum Press, ©1995$w(OCoLC)604251952
776 08 $iOnline version:$tVaccine design.$dNew York : Plenum Press, ©1995$w(OCoLC)609344661
830 0 $aPharmaceutical biotechnology ;$vv. 6.
830 0 $aLanguage of science.
938 $aBaker & Taylor$bBKTY$c330.50$d330.50$i030644867X$n0002674709$sactive
938 $aBrodart$bBROD$n48544167$c$145.00
938 $aBaker and Taylor$bBTCP$n95016401
938 $aYBP Library Services$bYANK$n171410
029 1 $aAU@$b000011605682
029 1 $aDEBBG$bBV011225047
029 1 $aHEBIS$b071670394
029 1 $aNLGGC$b15493478X
029 1 $aNLM$b9513086
029 1 $aNZ1$b4784217
029 1 $aUKMGB$b006292492
994 $aZ0$bP4A
948 $hNO HOLDINGS IN P4A - 121 OTHER HOLDINGS